Recombinant human thrombopoietin - Sansheng PharmaceuticalAlternative Names: rhTPO -Sansheng Pharmaceutical
Latest Information Update: 18 Jan 2016
At a glance
- Originator Sansheng Pharmaceutical
- Class Recombinant proteins
- Mechanism of Action Thrombopoietin receptor agonists; Thrombopoietin stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Clinical Phase Unknown Haemophagocytic lymphohistiocytosis